Discover

TMDX
TransMedics Group, Inc.
110.93
4 x 110.32
2 x 139.98
bid
ask
-
2.28
2.01%
3 @ 04:00 PM
111.50 +0.57 (0.51%)
Ytd -8.81%
1y 17.79%
109.14
day range
114.09
89.98
52 week range
150.42
Open 114.07 Prev Close 113.21 Low 109.14 High 114.09 Mkt Cap 3.83B
Vol 790.67K Avg Vol 891.12K EPS 4.77 P/E 23.26 Forward P/E 30.74
Beta 2.08 Short Ratio 7.66 Inst. Own 111.33% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 05-05 50-d Avg 120.82 200-d Avg 123.04 1yr Est 155.00
Earning
Date For Estimate Reported Surprise surprise %
2026-05-05 2026-03 0.62 N/A N/A N/A
2026-02-24 2025-12 0.41 0.57 0.16 39.02%
2025-10-29 2025-09 0.37 0.66 0.29 78.38%
2025-10-29 2025-09 0.37 N/A N/A N/A
2025-07-30 2025-06 0.48 0.92 0.44 91.67%
2025-07-30 2025-06 0.48 N/A N/A N/A
Upgrade / Downgrade
Date Firm Action From To
2026-04-06 Evercore ISI Group Upgrade Outperform Outperform
2026-03-09 Stifel Upgrade Hold Hold
2026-02-25 JP Morgan Upgrade Neutral Neutral
2026-02-25 Oppenheimer Upgrade Outperform Outperform
2026-02-25 Piper Sandler Upgrade Overweight Overweight
2026-02-25 Evercore ISI Group Upgrade Outperform Outperform
Profile
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Insider Holder
Date Name Relation Quantity Description
2026-02-17 CECERE GIOVANNI Officer 19.06K Stock Award(Grant)
2026-03-01 CORCORAN NICHOLAS Officer 29.83K Sale
2024-06-02 GORDON STEPHEN Chief Financial Officer 21.30K Sale
2025-11-16 HASSANEIN WALEED H Chief Executive Officer 0.00 Purchase
2026-03-03 HERNANDEZ GERARDO Chief Financial Officer 14.69K Sale
2025-05-21 KANIA EDWIN M JR Director 306.95K Stock Award(Grant)
Institution Ownership
Report Date Organization Position Value Percentage
2025-12-30 Blackrock Inc. 5.40M 598.49M 15.62%
2025-12-30 FMR, LLC 5.08M 563.20M 14.70%
2025-12-30 Vanguard Group Inc 3.61M 399.93M 10.44%
2025-12-30 State Street Corporation 1.28M 141.45M 3.69%
2025-12-30 UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 996.88K 110.58M 2.89%
2025-12-30 Goldman Sachs Group Inc 965.93K 107.15M 2.80%
Fund Ownership
Report Date Organization Position Value Percentage
2026-02-27 iShares Trust-iShares Core S&P Small-Cap ETF 2.07M 229.66M 6.00%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 1.02M 113.24M 2.96%
2026-02-27 iShares Trust-iShares Russell 2000 ETF 816.50K 90.57M 2.36%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund 736.61K 81.71M 2.13%
2026-02-27 Fidelity Contrafund-Fidelity Advisor New Insights Fund 614.30K 68.14M 1.78%
2026-02-27 Variable Insurance Products Fund II-VIP Contrafund Portfolio 589.60K 65.40M 1.71%